Mark Lawler

Sorcha Eastwood MP Verified account @SorchaEastwood · Feb 11

🙌 Minister commits to supporting all efforts to tackle cancer 🙌

Cancer doesn't stop at borders and neither should our efforts to tackle it!!

I was delighted to hear positive support today for my efforts to encourage the fight against cancer to be cross-border and between islands.

The work of the All-Island Cancer Research Institute @QUBCancerProf is the template and their work needs to be praised and supported!

Everyone deserves the best treatment and supports as they go through cancer.

I won't stop until we get there 🙏💪

View quoted post on X

The Johnston Cancer Research Centre @QubCancer · Jan 9

Join us for a JCRC Seminar on Wed 14 Jan at 12:30 with @QUBCancerProf & @DrPipDunne!
JCRC Basement Seminar Room, all welcome!

View quoted post on X

Department of Health @healthdpt · Nov 20, 2025

The Health Minister has published a new Cancer Research Strategic Framework for Northern Ireland.

Minister Nesbitt said the framework showed a "clear commitment to strengthening cancer research in Northern Ireland".

👉 Read more: t.ly/Gqgmy @QUBCancerProf @CR_UK

View quoted post on X

alphavestcapital.com Verified account @alphavestcap · Nov 11, 2025

x.com/TheLancetOncol… $nwbo @alphavestcap
x.com/andrewcaravell…

See new posts
Conversation
Andrew Caravello, DO@andrewcaravello🧬 The Week the System Learned to Heal Itself How $NWBO #DCVax®, #Eden®, and #AdventBioServices Became the Living Architecture of Britain’s National Cancer Control Plan TLDR In one week at the end of 2025, three decisions aligned the United Kingdom’s scientific, legal, and industrial machinery. • 5 Nov 2025: the House of Lords released Bleeding to Death (HL 192), a report warning that Britain’s life-science economy was “bleeding out.” • 6 Nov 2025: the patient-rights framework championed by Mark Lawler and colleagues—first outlined in The Lancet Oncology and amplified in autumn 2025—was presented as ten measurable principles for a national cancer plan. • 23 Jul 2025: months earlier, the MHRA had enacted Statutory Instrument 2025 No. 87, the first regulation to legalise modular, telemetry-verified manufacturing of advanced therapies, with operational guidance published that October. Within days, Northwest Biotherapeutics completed its acquisition of Advent BioServices (24 Oct 2025), joining research, automation, and production inside a single operating system. DCVax®, Eden®, and Advent together formed what those policy shifts demanded: a health system capable of learning in real time. 📷 I. The Lancet Ignition The first week of November 2025 opened quietly, but its documents carried the pulse of reform. In The Lancet Oncology, a ten-principle framework—originally published two years earlier and now revived in Parliament—mapped how a national cancer plan (NCCP) could move the country “from expectation to entitlement.” The authors urged government to legislate patient rights, build small empowered delivery units, publish live dashboards, and hard-wire accountability into law. It read less like rhetoric than a manual for immunity. A day earlier, the House of Lords had issued a more clinical chart note. Bleeding to Death (HL 192) described the UK’s innovation economy as a patient in haemorrhagic shock. Capital was fleeing; early-stage firms sold too soon; pension funds that once sustained British research had withdrawn. “The UK is bleeding out,” the report concluded. Its call for a National Council for Science and Growth, co-chaired by the Prime Minister and Chancellor, was a plea for coordinated resuscitation. Meanwhile, a new legal framework had taken effect. The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025 — Statutory Instrument No. 87 gave form to a decade of experimentation: advanced therapies could now be produced safely at or near the point of care, under continuous digital supervision. Britain’s legal code had, in effect, developed an immune reflex. Together these three actions—the Lords’ diagnosis, the policy prescription, and the MHRA’s law—formed a single response. Ethics supplied motive, economics restored circulation, regulation provided structure. 📷 Legislate Patient Rights → Access to the Immune System  Under SI 87 (2012) clinicians may manufacture autologous therapies when no licensed alternative exists. DCVax® embodies that law: a patient’s monoc1️⃣ 0.075em; margin-right: 0.075em; height: 1.2em; width: 1.2em; vertical-align: -20%;"> Create a Small Empowered Unit → Advent BioServices  At Sawston in Cambridge, Advent built an 88 000 sq ft GMP facility—compact, licensed, digitally auditable—producing DCVax-L for commercial supply under MHRA oversight. 📷 Publish a Core Indicator Set → Eden’s Dashboard  Inside each Eden® bioreactor, sensors stream oxygen, pH, and cytokine data to control software. Those metrics could feed directly into national dashboards, making progress as visible as waiting-time targets. 📷 Fund Scale, Not Pilots  Britain once expanded radiotherapy through national investment; cell therapy demands the same logic. Each Eden unit is a civi4️⃣ight: 1.2em; width: 1.2em; vertical-align: -20%;"> Put Equity First  Because DCVax® uses a patient’s own cells, eligibility is universal. Fairness is engineered. 📷 Hard-wire Survivorship  Long-tail survivors from the phase III trial show that immune memory outlasts therapy. Policy can learn to do the same. 📷 Build Capability, Not Headcount  Automation multiplies human capacity without exhaustion; one technician can supervise multiple pods with identical results. 7️⃣ vertical-align: -20%;"> Be Honest About Trade-offs  Every batch record is digital; every parameter traceable. Transparency is both ethic and quality system. Together these principles compose a genome for governance—one that detects error, responds in time, and remembers. What The Lancet Oncology outlined in theory, Eden and Advent were already demonstrating in practice. 📷 III. The Law Finds a Body — Statutory Instrument 2025 No. 87 Every organism needs a skeleton. Britain grew one in 2025. Statutory Instrument 2025 No. 87 converted scattered pilot exemptions into a permanent framework. Signed 23 January, in force 23 July, and detailed by the MHRA that October, it authorised what scientists had long envisioned: safe, digitally monitored manufacture of therapies at the point of care. Developers can now apply for a “decentralised manufacture” designation if they demonstrate clear clinical benefit—sho9️⃣ retains product-release authority. For the first time, law and biology spoke the same language: feedback and control. Hospitals could serve as manufacturing nodes, tethered by telemetry to the control site. Inspectors could observe every temperature curve in real time. Oversight became continuous rather than episodic. Economically, the change was radical and quiet. Instead of one capital-intensive factory feeding the nation, modular nodes could grow wherever need arose—distributed yet disciplined, like an immune network. In a country long accused of centralisation, SI 2025/87 proved that trust and traceability could scale together. It gave the UK a skeleton ready for the tissue of innovation growing around it. 📷 IV. The House of Lords and the Circulation of Capital A body can be rich in oxygen yet die of poor flow. That was the verdict of Bleeding to Death (HL 192). Britain’s science base remained strong—its heart still beating—but capital no longer circulated. Pension funds had retreated from risk; only a fraction of assets stayed in domestic equities. An economy that could incubate ideas could not sustain them. The report prescribed transfusion: treat science as infrastructure. Create a National Council for Science and Growth, reform procurement, unlock pensions, and re-establish circulation. Read beside the cancer-plan framework, the resonance was unmistakable. One report spoke of economic hypoxia, the other of clinical de⚖️qp9 r-dflpy8 r-k4bwe5 r-1kpi4qh r-pp5qcn r-h9hxbl" style="display: inline-block; margin-left: 0.075em; margin-right: 0.075em; height: 1.2em; width: 1.2em; vertical-align: -20%;"> V. The Right to Time and the Law of Immunity When oncologists proposed a legally enforceable right to timely treatment, they described not bureaucracy but morality. Every four-week delay raises mortality by nearly ten percent. England had missed its 62-day target for eight consecutive years. In Denmark, the law guarantees treatment within 28 days of diagnosis—and survival outcomes show it. Their solution was blunt: make time a duty. Hospitals that miss the 62-day window must fund care elsewhere. Without legal teeth, they wrote, “more patients will undoubtedly die.” The principle—time as contract—finds echo in DCVax-L’s manufacture. From leukapheresis to reinfusion takes 22 days. The biology runs to schedule: 72 hours for antigen uptake, 24 for co-stimulation, 12 for the interleukin-12 peak marking immune readiness. The precision that governs cells could now govern institutions. Britain already had the scaffold. Under SI 87 (2012) doctors may craft personalised therapies when no licensed option exists. Under SI 2025 No. 87 those therapies can be produced nearer to patients, in hospital-based modular units linked by telemetry to a central hub. A patient beyond the 62-day limit could, in principle, claim treatment under that provision. The clock becomes not administrative but vital. Across the Atlantic, the FDA’s Commissioner’s National Priority Voucher scheme rewards time-critical innovation with accelerated review. The same logic—delay costs life—now crosses borders. Automation gives that principle tangible form: every sensor reading is timestamped evidence that a public promise was kept. VI. The Digital Pulse — Data That Thinks Britain’s cancer-data infrastructure has matured into quiet competence. DATA-CAN links hospital records through a federated, privacy-preserving network that covers most of the NHS. Its purpose is circulation—data that feed, cleanse, and warn. Eden® extends that circulation to the cell itself. Inside each unit, dendritic cells converse with sensors monitoring pH, oxygen, and cytokines. Those signals feed into Emerson’s DeltaV system and Autolomous AutoloMATE, a cloud batch-record platform meeting global compliance standards. Every change—feeding, temperature, sterility—is timestamped and encrypted. The therapy becomes a sequence of verifiable events. At Advent’s control centre, dashboards stream in real time. Quality assurance shifts from paperwork to observation. Regulators can watch a therapy mature; oversight becomes a heartbeat. The process starts to resemble the immune system it serves—responsive, self-correcting, transparent. Today, DATA-CAN aggregates outcomes. As Eden® units embed within NHS trusts, their batch signatures could flow into that framework, marrying production data with clinical results. The London Care Record, operated by OneLondon, already links imaging and prescriptions across⏱ut judgment stays human. 📷 VII. Equity, Survivorship, and the Economy of Cure Equity in cancer care is survival shared fairly. Glioblastoma exposes the imbalance. Between 2013 and 2018, secondary-care costs for GBM patients in England topped £414 million. Average inpatient cost: £27 000. Complex cases: above £100 000 per year. Only one-third of spending went to treatment; the rest paid for complications, toxicities, emergencies, and palliation. A therapy that adds months of life reshapes both ethics and economics. DCVax-L’s phase III trial recorded 19.3 months median survival for newly diagnosed patients (16.5 for controls) and 13.2 months in recurrence (7.8 for controls). Thirteen percent lived five years—triple the historical norm. For the first time since 1999, a therapy moved the GBM curve. Each course now costs $200 000–$300 000, akin to CAR-T therapies. Automation through Eden® aims to cut that figure sharply by trimming labour and clean-room overhead and by processing multiple patients in parallel. NICE’s benchmark — £20 000–£30 000 per QALY — sets the goalpost. Reaching it demands an 80–90 percent cost reduction; Eden’s design makes that technically possible. Economic fairness mirrors biological fairness. Every patient’s cells form their own raw material. Each vaccine is unique yet uniformly produced. Equity becomes engineering. The macro-economy benefits too. Survivors work, pay taxes, and need fewer services. The Groundshot Commission’s 70:35 vision (70 percent long-term survival by 2035 across Europe) frames health as growth policy. Through La💻circulates. The once-bleeding system begins to heal. 📷 VIII. The Architecture of Integration — Advent, Eden, and Westminster By the final quarter of 2025, the country’s reforms had converged into a visible anatomy. The cancer-plan genome, the Lords’ circulation, and the MHRA’s skeleton were in place. What remained was coordination between the organs that made the body move. Advent BioServices — The Heart At Sawston, Advent’s facility beats at the centre of Britain’s new therapeutic metabolism. Its MHRA licence—one of the UK’s first for commercial cell-therapy manufacturing—authorises production for domestic use and export. The building reflects its purpose: glass-walled cleanrooms, cryostorage for millions of vials, and a control hub glowing with telemetry screens that chart every batch in progress. When Advent releases a dose, it fulfils not only a prescription but a public promise. On 24 October 2025, Northwest Biotherapeutics completed its acquisition of Advent, converting contractor into subsidiary and uniting research, manufacturing, and quality release under a single corporate spine. Vertical integration shortened feedback loops and eliminated duplicated margins. In a system often slowed by separation, it was an anatomical correction—the heart and arteries brought under one circulation. Flaskworks Eden — The Engine If Advent provides circulation, Eden® provides metabolism. Each unit is a sealed bioreactor where dendritic cells grow and learn. Automation replaces dozens of manual steps; digital data flow replaces binders of paper records. Emerson’s D♻️e travelled by committee; now it travels by data. Aggregated telemetry from Eden® units feeds to the Department of Health and Social Care and the Office for Life Sciences. Dashboards track three vital measures: – Timeliness: the share of patients treated within the 62-day legal window. – Efficacy: immune potency and survival outcomes. – Equity: access by region and demographic. When a signal drifts—a region misses its target, a batch underperforms—funding and oversight shift automatically. The state begins to act reflexively, not reactively. Statutory Instrument 2025 No. 87 — The Skeleton Every Eden® module across the UK remains tethered to Advent’s control hub through secure telemetry. Each distributed site functions as a vertebra protecting the spinal cord of data integrity. The result is decentralisation that still moves as one: flexibility without fragmentation. Sustainability Through Data The new model measures itself in evidence. Performance metrics—energy use, yield, turnaround—feed directly into Treasury models for outcome-based reimbursement. Budgets follow proof, not precedent. In economics as in physiology, efficiency sustains life. Friction and Resilience Even living systems burn energy. Scaling modular manufacture across hospitals will demand capital and a workforce fluent in both cell biology and automation. Ethical frameworks for AI and patient data will need continual renewal. These are not defects but metabolism—the maintenance cost of adaptation. The reward is measurable: a shift from indefinite maintenance therapy to one-time immune education. Cost and Saving Conventional glioblastoma care—surgery, chemoradiation, imaging, and palliation—often exceeds £100,000 per patient per year. Between 2013 and 2018, secondary-care costs alone reached £414 million in England. An autologous vaccine like DCVax®, produced once and monitored digitally, front-loads expense but erases years of downstream cost: fewer emergency admissions, reduced toxicity, less hospice reliance. Each long-term survivor represents avoided expenditure and regained productivity. The fiscal curve inverts—the more citizens cured, the cheaper the system becomes to sustain. The Human Equation In Sawston’s control room, technicians watch dendritic cells awaken. Cytokine graphs rise and stabilise; a valve adjusts, the medium clears. The scene is quiet but consequential. Precision meets patience; machine and biology share the same rhythm. Each completed batch marks another patient’s chance and another proof that policy, technology, and care can act in unison. The Whole Desig🏗h infrastructure behaves like a living body—responsive, self-aware, and proportionate. 📷 IX. The State That Learns By December 2025, Britain’s reforms—scientific, legal, economic—had begun to operate as one body. The cancer-plan framework served as the genome; the Lords’ report restored circulation; the MHRA’s regulation supplied bones and nerves. The outcome was not spectacle but function: a system learning to heal itself. Each layer mirrored another. Advent’s cleanrooms contract and release like heart chambers. Eden®’s automation hums like neural tissue, transmitting signals across the regulatory network. Westminster’s dashboards flicker like synapses processing feedback. Recognition, response, memory—the triad that defines immunity—now describes governance as well. For scientists, the synchrony was vindication. For patients, it was proof that a bureaucracy could learn empathy. For policymakers, it was evidence that data, when trusted, can become conscience. This transformation was procedural rather than dramatic. A law amended in January generated datasets by July and a budget revision by December. The delay between diagnosis and response had collapsed from years to months. The system had learned to clot before it bled. What began as an emergency diagnosis—“the UK is bleeding out”—became a demonstration of recovery. The same feedback principles that govern immunity now governed policy: detect error, correct it, remember. Whether by deliberate design or institutional convergence, the structure that emerged in autumn 2025 embodied the logic of a living organism—real-time sensing, rapid response, lasting memory. A nation that once measured progress in hospitals built and budgets spent now measures it in time saved, data shared, and lives extended. Compassion is now quantifiable; intelligence, procedural. The United Kingdom is not merely modernising its health service—it is teaching it to think. When policy meets the cell, when law breathes and data feels, governance achieves something close to biology’s highest art. The patient is no longer bleeding. The patient is learning. Sources House of Lords Science and Technology Committee. Bleeding to Death: The Science and Technology Growth Emergency (HL Paper 192, Nov 2025). Lawler M. et al. The Lancet Oncology: “A Deliverable National Cancer Control Plan for the UK” (original 2023 publication; amplified in 2025 policy debate). MHRA. The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025 (SI 2025 No. 87) and October 2025 guidance. Northwest Biotherapeutics. “Acquisition of Advent BioServices Ltd Closed.” Press release, 24 Oct 2025. Advent BioServices. “MHRA License for Commercial Manufacturing at Sawston Facility.” Press release, Mar 2023. Flaskworks LLC / NWBO. Technical briefings on Eden® automation (2024–2025). Liau L.M. et al. JAMA Oncology (2022): “Association of Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination with Extension of Survival Among Patients with Glioblastoma.” Imperial College London (GlioCova). Cost of Treating Adult Glioblastoma Patients in England (2013–2018). NICE. Guidance in Development ID836: DCVax-L for Treating Glioblastoma. DATA-CAN programme overview and OneLondon’s London Care Record impact evaluation (2024–2025).QuoteThe Lancet Oncology@TheLancetOncol·22h📷Comment: A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home Authors: @QUBCancerProf, @DrCaryAdams, Eduardo Pisani, @YannickRomero, @sar_quinlan, & @prof_price thelancet.com/journals/lanon… edited7:36 AM · Nov 11, 2025·Views110

View quoted post on X

The Lancet Oncology @TheLancetOncol · Nov 10, 2025

🆕Comment: A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home

Authors: @QUBCancerProf, @DrCaryAdams, Eduardo Pisani, @YannickRomero, @sar_quinlan, & @prof_price

thelancet.com/journals/lanon…

View quoted post on X